Involvement of quinolinic acid in AIDS dementia complex - PubMed (original) (raw)

Review

Involvement of quinolinic acid in AIDS dementia complex

Gilles J Guillemin et al. Neurotox Res. 2005.

Abstract

Human immunodeficiency virus (HIV) infection is often complicated by the development of acquired immunodeficiency syndrome (AIDS) dementia complex (ADC). Quinolinic acid (QUIN) is an end product of tryptophan, metabolized through the kynurenine pathway (KP) that can act as an endogenous brain excitotoxin when produced and released by activated macrophages/microglia, the very cells that are prominent in the pathogenesis of ADC. This review examines QUIN's involvement in the features of ADC and its role in pathogenesis. We then synthesize these findings into a hypothetical model for the role played by QUIN in ADC, and discuss the implications of this model for ADC and other inflammatory brain diseases.

PubMed Disclaimer

Similar articles

• CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
  Valle M, Price RW, Nilsson A, Heyes M, Verotta D. Valle M, et al. Brain. 2004 May;127(Pt 5):1047-60. doi: 10.1093/brain/awh130. Epub 2004 Mar 10. Brain. 2004. PMID: 15013955
• Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
  Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, Rosenfeld JV, Walker DW, Guillemin GJ, Morganti-Kossmann MC. Yan EB, et al. J Neuroinflammation. 2015 May 30;12:110. doi: 10.1186/s12974-015-0328-2. J Neuroinflammation. 2015. PMID: 26025142 Free PMC article.
• Neurocytotoxity of quinolinic acid in human brain cultures.
  Kerr SJ, Armati PJ, Brew BJ. Kerr SJ, et al. J Neurovirol. 1995 Dec;1(5-6):375-80. doi: 10.3109/13550289509111027. J Neurovirol. 1995. PMID: 9222380
• Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
  Guillemin GJ, Meininger V, Brew BJ. Guillemin GJ, et al. Neurodegener Dis. 2005;2(3-4):166-76. doi: 10.1159/000089622. Neurodegener Dis. 2005. PMID: 16909022 Review.

Cited by

• Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage.
  Sheipouri D, Braidy N, Guillemin GJ. Sheipouri D, et al. Int J Tryptophan Res. 2012;5:15-25. doi: 10.4137/IJTR.S9835. Epub 2012 Jul 3. Int J Tryptophan Res. 2012. PMID: 22837645 Free PMC article.
• Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.
  Sperner-Unterweger B. Sperner-Unterweger B. Drugs. 2005;65(11):1493-520. doi: 10.2165/00003495-200565110-00004. Drugs. 2005. PMID: 16033289 Review.
• The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.
  Ting KK, Brew B, Guillemin G. Ting KK, et al. Neurotox Res. 2007 Dec;12(4):247-62. doi: 10.1007/BF03033908. Neurotox Res. 2007. PMID: 18201952 Review.
• Neurodegeneration and ageing in the HAART era.
  Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Brew BJ, et al. J Neuroimmune Pharmacol. 2009 Jun;4(2):163-74. doi: 10.1007/s11481-008-9143-1. Epub 2008 Dec 6. J Neuroimmune Pharmacol. 2009. PMID: 19067177 Review.
• The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.
  Byakwaga H, Boum Y 2nd, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW. Byakwaga H, et al. J Infect Dis. 2014 Aug 1;210(3):383-91. doi: 10.1093/infdis/jiu115. Epub 2014 Feb 28. J Infect Dis. 2014. PMID: 24585899 Free PMC article.

References

1. 1. AIDS. 1998 Mar 5;12(4):355-63 - PubMed
2. 1. Neurosci Lett. 1992 Oct 12;145(2):234-5 - PubMed
3. 1. Exp Neurol. 2001 Jan;167(1):196-204 - PubMed
4. 1. Br J Pharmacol. 2002 Mar;135(6):1435-42 - PubMed
5. 1. Neurology. 1991 Jan;41(1):69-74 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer